Medical News

RSS

Study finds risk of toxicity in Phase I radiation oncology clinical trials

Risks to patients enrolled in Phase I radiation oncology clinical trials are higher than previously appreciated, according to a study conducted by researchers from the Kimmel Cancer Center at Jefferson. The findings will be presented at the American Society of Radiation Oncology (ASTRO) annual meeting in San Diego.

3 Nov 2010

Scientists recommend research on bacterial vaccine to prevent influenza

Secondary infections with bacteria such as Streptococcus pneumoniae, which causes pneumonia, were a major cause of death during the 1918 flu pandemic and may be important in modern pandemics as well, according to a new article in the Journal of Infectious Diseases co-authored by David M. Morens, M.D., senior advisor to the director of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

3 Nov 2010

Visual attention diminishes with age

A University of Toronto study shows that visual attention -- the brain's ability to selectively filter unattended or unwanted information from reaching awareness -- diminishes with age, leaving older adults less capable of filtering out distracting or irrelevant information.

3 Nov 2010

Pharma companies in Asia Pacific shift to high-risk, high-return research and development

Pharmaceutical companies in the Asia Pacific region are increasingly adapting their business models from the production of generic drugs towards more high-risk, high-return research and development, according to a new report released today by CMR International, a Thomson Reuters business.

3 Nov 2010

New global map shows distribution of sickle cell gene

At a global scale, the sickle cell gene is most commonly found in areas with historically high levels of malaria, adding geographical support to the hypothesis that the gene, whilst potentially deadly, avoids disappearing through natural selection by providing protection against malaria.

3 Nov 2010

Curemark awarded QTDP grant to advance development of CM-AT for autism

Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that it has been awarded a grant by the United States government under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product CM-AT for autism. CM-AT is presently in Phase III clinical trials at 18 sites around the US.

3 Nov 2010

Celsion receives $244,000 grant under QTDP program

Celsion Corporation today announced that the company has been awarded a $244,000 grant under the Qualifying Therapeutic Discovery Project (QTDP) program under The Patient Protection and Affordable Care Act of 2010 (PPACA).

3 Nov 2010

CR4354 antibody uses crosslinking mechanism to neutralize West Nile virus

Researchers have learned the structure that results when an antibody binds to the West Nile virus, neutralizing the virus by locking up its infection mechanism. The information could help scientists develop a vaccine against the mosquito-borne disease.

3 Nov 2010

Cardiovascular Systems enters settlement agreement with ev3

Cardiovascular Systems, Inc. announced today that it has entered into a settlement agreement with ev3, Inc., now part of Covidien plc. The agreement dismisses all claims and counterclaims in the employment lawsuit between the two companies. The litigation stems from a suit ev3 originally filed against CSI in 2007 related to employees who joined CSI from ev3.

3 Nov 2010

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced that three of the Company's therapeutic development programs, VIMOVO (naproxen / esomeprazole magnesium) (formerly PN400), PA32540 and PA65020, qualified to receive federal grant funding under The Patient Protection and Affordable Care Act.

3 Nov 2010

Synergenz awarded $94,836 research grant under federal QTDP program

Synergenz BioScience, Inc., a leader in predictive risk stratification for smoking-related lung cancer, was awarded a research grant under the Federal Government's Qualifying Therapeutic Discovery Project (QTDP) program.

3 Nov 2010

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, announced today that it has established a Scientific Advisory Board to help advance the company's research and clinical studies in type 1 diabetes.

3 Nov 2010

Study suggests heredity may play a role in determining infant's susceptibility to AOP

A potentially life-threatening challenge characterized by pauses in breathing that can last for more than 20 seconds, apnea of prematurity (AOP) affects more than 50 percent of premature infants and is almost universal in the smallest of preemies. Caused in part by an underdeveloped central nervous system that can't adequately regulate breathing outside of the womb, especially during sleep, AOP is not yet fully understood by scientists and remains a grave concern among neonatologists and parents alike.

3 Nov 2010

Study: Illnesses and injuries that restrict activity linked to worsening functional ability in older adults

A study by Yale School of Medicine researchers reveals that the illnesses and injuries that can restrict the activity of older adults or land them in the hospital are linked to worsening functional ability, especially among those who are physically frail. The report appears in JAMA's November 3 theme issue on aging.

3 Nov 2010

Image Guided IMRT preserves sexual function in men after prostatectomy

Men battling prostate cancer who receive Image Guided Intensity Modulated Radiation Therapy after undergoing prostatectomy have an excellent chance of retaining sexual function, according to a study by Allegheny General Hospital (AGH) cancer specialists presented this week at the annual meeting of the American Society for Therapeutic Radiation and Oncology in San Diego.

3 Nov 2010

OncoMed receives $1.2 million to support therapeutic programs under QTDP program

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, announced today that it has been awarded $1.2 million to support five distinct therapeutic programs under the U.S. Government's Qualifying Therapeutic Discovery Project program.

3 Nov 2010

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

Ortho-McNeil-Janssen Pharmaceuticals, Inc. today announced it has entered into a supply and distribution agreement with Watson Laboratories, Inc. to distribute an authorized generic version of CONCERTA (methylphenidate HCl extended-release tablets).

3 Nov 2010

UIC awarded $12M to study acquired and familial causes of heart failure

Researchers at the University of Illinois at Chicago have been awarded more than $12 million by the National Heart, Lung, and Blood Institute to investigate both the acquired and familial causes of heart failure -- with the aim of identifying markers for diagnosis and targets for cures.

3 Nov 2010

Neoprobe receives $244,479 grant under QTDP program

Neoprobe Corporation a diversified developer of innovative oncology surgical and diagnostic products, today announced that it has been awarded a grant of $244,479 under the qualifying therapeutic discovery project program established under Section 48D of the Internal Revenue Code.

3 Nov 2010

CTI granted additional 180 days to regain compliance with NASDAQ minimum bid price rule

Cell Therapeutics, Inc. today announced that The NASDAQ Stock Market has granted CTI an additional 180 days to regain compliance with NASDAQ's $1.00 minimum bid price rule under NASDAQ Marketplace Rule 5550(a)(2)). Previously, on May 3, 2010, CTI was notified by NASDAQ that CTI did not meet the minimum bid price rule required for continued listing and was provided until November 1, 2010 to achieve compliance.

3 Nov 2010

Medical News

Study finds risk of toxicity in Phase I radiation oncology clinical trials

Scientists recommend research on bacterial vaccine to prevent influenza

Visual attention diminishes with age

Pharma companies in Asia Pacific shift to high-risk, high-return research and development

New global map shows distribution of sickle cell gene

Curemark awarded QTDP grant to advance development of CM-AT for autism

Celsion receives $244,000 grant under QTDP program

CR4354 antibody uses crosslinking mechanism to neutralize West Nile virus

Cardiovascular Systems enters settlement agreement with ev3

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

Synergenz awarded $94,836 research grant under federal QTDP program

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Study suggests heredity may play a role in determining infant's susceptibility to AOP

Study: Illnesses and injuries that restrict activity linked to worsening functional ability in older adults

Image Guided IMRT preserves sexual function in men after prostatectomy

OncoMed receives $1.2 million to support therapeutic programs under QTDP program

OMJPI enters agreement with Watson to distribute generic version of CONCERTA tablets

UIC awarded $12M to study acquired and familial causes of heart failure

Neoprobe receives $244,479 grant under QTDP program

CTI granted additional 180 days to regain compliance with NASDAQ minimum bid price rule

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News